JAK2 and myeloproliferative disorder: It has recently been discovered that a single-site, clonal, gain-of-function mutation of the tyrosine kinase, JAK2 (JAK2 V617F) is present in myeloid cells from the majority of patients with chronic myeloproliferative disorders (CMDs) (Goldman, 2005; Kaushansky, 2005).